Skip to main content

lutetium lu 177 vipivotide tetraxetan

Generic: Lutetium Lu 177 Vipivotide Tetraxetan

lutetium lu 177 vipivotide tetraxetan: 7 clinical trials tracked.

lutetium lu 177 vipivotide tetraxetan evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about lutetium lu 177 vipivotide tetraxetan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trials (7)

Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)

NCT07200830·Phase 3
Recruiting

Primary endpoint: Overall survival (OS)

InterventionalRandomizedopen1,524 targetStarted 2026-03Completion 2034-0950 sites · United StatesAlliance for Clinical Trials in Oncology

A Phase 2 Study of Biomarker-Modulated PSMA Theranostics

NCT06526299·Phase 2
Recruiting

Primary endpoint: Prostate-specific antigen (PSA) progression-free survival (PFS)

Interventionalopen51 targetStarted 2025-04Completion 2027-123 sites · United StatesUniversity of Washington

PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)

NCT06632977·Phase 2
Recruiting

Primary endpoint: Objective Response

Interventionalopen474 targetStarted 2025-02Completion 2034-1050 sites · United StatesAlliance for Clinical Trials in Oncology

Vorinostat to Augment Response to 177Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer

NCT06145633·Phase 2
Recruiting

Primary endpoint: Proportion of patients who convert from prostate-specific membrane antigen (PSMA) low to PSMA high

Interventionalopen15 targetStarted 2024-09Completion 2027-121 site · United StatesFred Hutchinson Cancer Center

Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY)

NCT06288113·Phase 2
Recruiting

Primary endpoint: 12-month overall survival

Interventionalopen40 targetStarted 2024-08Completion 2028-011 site · United StatesJonsson Comprehensive Cancer Center

A Phase 2 Randomized Trial in Patients With Metastatic Castration Resistant Prostate Cancer to Determine the Efficacy of a Flexible Dosing Schedule of Lu-PSMA Treatment up to 12 Cycles Including Potential Treatment Holiday Periods in Comparison to the Standard Fixed Dosing Schedule of Six Cycles Every Six Weeks (FLEX-MRT)

NCT06216249·Phase 2
Recruiting

Primary endpoint: 2-year survival rate

InterventionalRandomizedopen90 targetStarted 2024-08Completion 2028-121 site · United StatesJonsson Comprehensive Cancer Center

Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy

NCT05113537·Phase 1/Phase 2
Recruiting

Primary endpoint: Recommended phase 2 dose (Part A)

Interventionalopen30 targetStarted 2022-07Completion 2028-121 site · United StatesVadim S Koshkin